Comprehensive Assessment of Retinal Vasculature (CARV)

视网膜血管系统综合评估（CARV）

基本信息

批准号：
8644662
负责人：
Vinayak S Joshi
金额：
$ 15.23万
依托单位：
VISIONQUEST BIOMEDICAL, LLC
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-03-01 至 2015-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8644662
关键词：
Address Agreement Algorithms Area Arteries Blood Vessels Caliber Cardiovascular Diseases Classification Clinical Copper Databases Detection Diabetic Retinopathy Doctor of Philosophy Effectiveness Embolism Environment Evaluation Reports Event Eye Future Goals Gold Health Healthcare Hypertension Hypertensive Retinopathy Image Incidence Institutes Lesion Life Manuals Measurement Measures Methods Ophthalmology Optic Disk Pattern Performance Phase Physician Executives Principal Investigator Process Provider Reader Reporting Research Retina Retinal Retinal Diseases Risk Rural Community Scientist Silver Software Tools South Texas Specialist Stroke System Systemic disease Techniques Telemedicine Time Training Veins Vision cost diabetic experience graphical user interface innovation programs public health relevance retina blood vessel structure screening tool

项目摘要

Summary Teleretinal programs have expanded in recent years, primarily to screen for diabetic retinopathy. Accurate and consistent assessment of the retinal vasculature, which often sustains damage as a result of cardiovascular disease, would advance teleretinal screening in terms of robustness and cost. Unfortunately, assessing changes to the retinal vasculature and quantifying abnormalities in retinal images has proven more difficult. Semi-automatic methods are reported to reduce grader variability, but they are time-consuming, requiring extensive reader interaction, thus limiting the overall effectiveness of a teleretinal screening program. VisionQuest Biomedical and its collaborator, the Retina Institute of South Texas (RIST), will demonstrate a software tool for comprehensive assessment of retinal vasculature (CARV) to aid readers in the quantitative characterization of vascular abnormalities and identification of those images with features indicative of potential sight-threatening or life-threatening conditions. CARV will provide the reader real-time artery to vein ratio (AVR) measurements, an accepted clinical value for determining risk of future stroke or hypertensive events, as well as measurements associated with branching patterns and tortuosity. It will also incorporate detection algorithms for features such as copper and silver wiring, AV nicking, and emboli. Our goal is to provide an aid to the retinal grader for detecting and quantifying common retinal vessel abnormalities with high agreement with the gold standard, a retinal specialist. In this Phase I we will also implement clinically accepted quantitative measurements for vasculature parameters. CARV, which can be integrated into a teleretinal system for diabetics, will allow graders to consistently identify signs of hypertensive retinopathy and CVD-related conditions and providers to exploit the full potential of teleretinal screening.

概括端计划近年来已经扩展，主要是为了筛查糖尿病视网膜病。对视网膜脉管系统的准确且一致的评估，通常可以维持由于心血管疾病的损害，将从稳健性和成本。不幸的是，评估视网膜脉管系统的变化和量化视网膜图像中的异常已被证明更加困难。报告了半自动方法为了减少分级变异性，但它们很耗时，需要广泛的读者相互作用，从而限制了端筛选程序的总体有效性。 VisionQuest Biomedical及其合作者南德克萨斯州视网膜研究所（RIST）将展示用于全面评估视网膜脉管系统（CARV）的软件工具以帮助读者是血管异常的定量表征和鉴定的读者具有指示潜在的观察或威胁生命条件的特征的图像。 CARV将提供读者实时动脉与静脉比率（AVR）测量值确定未来中风或高血压事件的风险的临床价值，以及与分支模式和曲折相关的测量。它也将合并检测算法，例如铜和银线，AV Nicking和Emboli。我们的目标是为视网膜分级器提供援助，以检测和量化常见的视网膜船只异常与视网膜专家黄金标准高度一致。在这个第一阶段我们还将实施临床上接受的脉管系统的定量测量参数。 CARV可以集成到糖尿病患者的端机系统中，将允许分级器始终确定高血压视网膜病和CVD相关疾病的迹象以及提供者可以利用远期筛查的全部潜力。